Neurodegeneration and neuroprotection in Parkinson disease.
about
The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old ageThe role of oxidative stress in Parkinson's diseaseSystematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activitiesMechanism of Anti-α-Synuclein ImmunotherapyNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseThe Synaptic Function of α-SynucleinChanges in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamineVascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacityMHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degenerationBehavioral phenotyping of mouse models of Parkinson's disease.Embryonic development of selectively vulnerable neurons in Parkinson's disease.Normalizing EMG to Background Muscle Activation Masks Medication-Induced Reductions in Reflex Amplitudes in Parkinsonian Rigidity.α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease.Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease.Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1.VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.Programmed cell death and new discoveries in the genetics of parkinsonism.Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers.Metabolomics and in-silico analysis reveal critical energy deregulations in animal models of Parkinson's disease.Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts.Inhibition of store-operated calcium entry attenuates MPP(+)-induced oxidative stress via preservation of mitochondrial function in PC12 cells: involvement of Homer1a.Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's diseaseEffect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated ratsAmplitude- and velocity-dependency of rigidity measured at the wrist in Parkinson's disease.Plasma selenium is positively related to performance in neurological tasks assessing coordination and motor speedDopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.Nrf2-mediated protection against 6-hydroxydopamineCaffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor.Central dopaminergic system and its implications in stress-mediated neurological disorders and gastric ulcers: short review.Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic.Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatmentSelective brain penetrable Nurr1 transactivator for treating Parkinson's disease.The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
P2860
Q21090191-993FEBC3-6430-425E-958C-318D518BDC85Q24307946-C1AD6433-53BF-4620-B970-609E9C6EC0A3Q26269871-D5542F40-0C1B-421D-955F-A22D4430FB8BQ26772943-7BC15DE7-215D-417C-9303-8189D9F645F6Q27301283-39891E13-C5D1-4BE1-A7A2-6C8E61B56731Q27694711-F9336A27-F555-4B3C-B728-E24170D9866FQ28583030-D7398F68-832B-44B8-A455-483A4E5B1281Q33562727-2107E644-2D0A-4DC9-94F4-5AF7960257D9Q33577056-E25417F5-DCC5-49BF-9F25-B5CBF7D2A4F0Q33617472-CCFF7F76-1A4F-4988-A56B-E2759298FA05Q33625527-99969049-483A-4F10-83CA-AA9E36EFD0E7Q33820609-503CEC6F-1E36-428E-A54C-AB9FC23E4EE7Q33835242-13B7C068-B678-4A48-9396-3A9EB21947F4Q33865035-BD679A92-0125-4F90-ADB0-80A9AA0CD895Q33911222-3279B6F4-C6D9-4231-B89A-D643092E54CBQ33925236-BF708972-1E4E-470B-9478-C251C7D341D4Q34576781-B96E848B-2214-4DF3-9EB7-075250C88CFAQ34595165-C189BBF0-C051-4E34-AA97-A0D5A7898E56Q34687382-60310B57-F4EC-4BC2-B000-F000E3D09357Q34859364-2722B6D5-9606-4FCA-9E5A-36F1688A99F5Q34901494-4D7DEDB2-680F-4EE4-900D-680E4B842912Q34919307-25B6DA82-1D98-42AA-86BD-ED598B7EF9E4Q35008102-09A32929-CDE9-4F87-9B6C-2553C324A461Q35073154-14AAB465-7125-4FE4-A7E0-FC68CA57BBE0Q35157431-7665F037-A19C-42C1-8F68-8EF07827E8E1Q35635814-A034ABC4-A80B-4EC2-86E1-C318DACB4833Q35678250-05E3DD5C-40DC-4DCF-904E-7E9D2C62E054Q35726654-15FC38B0-8208-409F-BA8F-869B3F97CA47Q35828317-7DCDCB7D-DD7B-4D78-9523-60DB26026B4AQ35834043-54733977-1F94-4DF6-8CBF-2DABEAFFB7EEQ35897729-8437EE97-3892-48E3-BE29-D9E3E72DF06BQ36114124-3DC7FB94-1328-4F24-86ED-92473AB94F86Q36158998-F54D0C79-4466-4DB5-A7E4-24985733DAC5Q36253550-C9E37A3D-ABE4-451F-AD23-65E952F8C91FQ36364388-FD40E838-F88B-40B0-ADE9-928107A5A14DQ36724965-DDA8F69D-C7D7-483B-A406-0A9D9A57961EQ36809514-A0A85ED0-2DF0-48F5-B3BD-286899E0941AQ36908421-370AF88A-01C8-42D8-8136-6CCE96B75D22Q36946543-6F58767D-1022-48AB-B59F-225CE7636F4BQ37003482-97D59C94-0262-4E3C-B446-796FED9BBAAE
P2860
Neurodegeneration and neuroprotection in Parkinson disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Neurodegeneration and neuroprotection in Parkinson disease.
@ast
Neurodegeneration and neuroprotection in Parkinson disease.
@en
type
label
Neurodegeneration and neuroprotection in Parkinson disease.
@ast
Neurodegeneration and neuroprotection in Parkinson disease.
@en
prefLabel
Neurodegeneration and neuroprotection in Parkinson disease.
@ast
Neurodegeneration and neuroprotection in Parkinson disease.
@en
P2860
P356
P1433
P1476
Neurodegeneration and neuroprotection in Parkinson disease.
@en
P2860
P304
P356
10.1602/NEURORX.1.1.139
P577
2004-01-01T00:00:00Z